Phaseline

Companies › Liquidia Technologies

Liquidia Technologies: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 3 Phase 3, 1 Phase 4; Cardiovascular; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Treprostinil (LIQ861)
Prostanoid IP receptor agonist
PTGIRPhase 4Pulmonary Arterial Hypertension (PAH); Primary Pulmonary Hypertension; Pulmonary Hypertension Due to Lung Disease (Disorder); Pulmonary Arterial HypertensionMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03992755Treprostinil (LIQ861)Phase 3Primary Pulmonary HypertensionCardiovascularMay 2025
NCT07759804Treprostinil (LIQ861)Phase 4Pulmonary Arterial Hypertension (PAH)CardiovascularMay 2027
NCT07285655Treprostinil (LIQ861)Phase 3Pulmonary Hypertension Due to Lung Disease (Disorder)CardiovascularJul 2029
NCT04691154Treprostinil (LIQ861)Phase 3Pulmonary Arterial HypertensionCardiovascularMar 2031

Targets

PTGIR (1)

Companies with the same targets

Insmed Johnson & Johnson (Janssen) United Therapeutics

Companies built like this

Trust Bio-sonics EVD Pharmacy and Medical Company Pulmovant EBI Anti Sepsis Agitated Solutions

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.